-
-
NCT00821600
-
Primary Citation Not Available
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameRisperidoneProduct NameRISPERDAL CONSTA®Therapeutic AreaNervous SystemProduct ClassPsycholepticsCondition StudiedSchizophreniaChemical SubgroupsN/APharmacological SubgroupsN/A
Sponsor Protocol NumberRIS-SCH-1012Enrollment24Data PartnerJohnson & Johnson% Female33.3%Mean/Median Age (Years)N/A% WhiteN/A
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2023-5502 : Development of a model to simulate the pharmacokinetics of drugs in patients with different characteristics to advance precision medicine
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4754 : Harnessing clinical trial data to inform real-world clinical decision making in the treatment of schizophrenia
- 2021-4705 : Inflammation and the Metabolic Syndrome in Psychosis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.